Kathmere Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Kathmere Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.14M	Buy	37,197 +14,023	+61%	+$805K	0.11%	138
2026 Q1	$1.41M	Buy	23,174 +12,880	+125%	+$751K	0.09%	159
2025 Q4	$555K	Buy	10,294 +4,897	+91%	+$236K	0.04%	298
2025 Q3	$243K	Sell	5,397 -3,851	-42%	-$180K	0.02%	441
2025 Q2	$428K	Sell	9,248 -326	-3%	-$16K	0.03%	309
2025 Q1	$584K	Sell	9,574 -1,064	-10%	-$62K	0.05%	219
2024 Q4	$602K	Buy	10,638 +2,656	+33%	+$148K	0.05%	197
2024 Q3	$413K	Buy	+7,982	New	+$374K	0.04%	234
2024 Q2	–	Sell	-4,096	Closed	-$222K	–	342
2024 Q1	$222K	Buy	+4,096	New	+$209K	0.03%	294
2023 Q3	–	Sell	-3,582	Closed	-$229K	–	268
2023 Q2	$229K	Buy	3,582 +70	+2%	+$4.69K	0.04%	208
2023 Q1	$243K	Sell	3,512 -969	-22%	-$68.3K	0.04%	175
2022 Q4	$322K	Buy	+4,481	New	+$338K	0.06%	136
2021 Q1	–	Sell	-2,531	Closed	-$157K	–	160
2020 Q4	$157K	Hold	2,531	–	–	0.03%	141
2020 Q3	$153K	Buy	+2,531	New	+$152K	0.04%	129
2020 Q1	–	Sell	-5,902	Closed	-$379K	–	87
2019 Q4	$379K	Buy	+5,902	New	+$338K	0.14%	68

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kathmere Capital Management's BMY Position: Q2 2026 in Review

Kathmere Capital Management increased its Bristol-Myers Squibb (BMY) stake by 61% in Q2 2026, buying an estimated $805K and bringing the position to 37,197 shares worth $2.14M. The position accounts for 0.11% of the portfolio, ranked #138.

Kathmere Capital Management first reported a position in BMY in Q4 2019 and has held it in 15 quarters since. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Kathmere Capital Management held 37,197 shares of Bristol-Myers Squibb worth $2.14M as of Q2 2026.
Kathmere Capital Management bought 14,023 Bristol-Myers Squibb shares in Q2 2026, an estimated $805K.
Bristol-Myers Squibb made up 0.11% of Kathmere Capital Management's portfolio in Q2 2026, its #138 holding.
Kathmere Capital Management first reported a position in Bristol-Myers Squibb in Q4 2019 and has held it in 15 quarters since.
2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.